SG11201407043PA - Method for the preparation of triazole compounds - Google Patents
Method for the preparation of triazole compoundsInfo
- Publication number
- SG11201407043PA SG11201407043PA SG11201407043PA SG11201407043PA SG11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA
- Authority
- SG
- Singapore
- Prior art keywords
- triazol
- morpholin
- keto
- enol
- internationales
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
Abstract
(12) NACH DEM VERTRAG UBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT) VEROFFENTLICHTE INTERNATIONALE ANMELDUNG (19) Weltorganisation fiir geistiges Eigentum Internationales Biiro _ (10) Internationale Veroffentlichungsnummer (43) Internationales Veroffentlichungsdatum 14. November 2013 (14.11.2013) WIPOIPCT WO 2013/167552 A1 (51) Internationale Patentklassifikation: C07D 403/14 (2006.01) C07D 249/04 (2006.01) (21) Internationales Aktenzeichen: (22) Internationales Anmeldedatum: (25) Einreichungssprache: (26) Veroffentlichungssprache: PCT/EP2013/059418 6. Mai 2013 (06.05.2013) Deutsch Deutsch (30) Angaben zur Prioritat: 12167152.3 8. Mai 2012 (08.05.2012) EP (71) Anmelder: BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Mullerstr. 178, 13353 Berlin (DE). (72) Erflnder: MILITZER, Hans-Christian; Waldweg 2, 51519 Odenthal (DE). EGGERT, Johannes; Johann- Sebastian-Bach-Str. 64, 61250 Usingen (DE). (74) Anwalt: BIP PATENTS; c/o Bayer Intellectual Property — GmbH, Creative Campus Monheim, Alfred-Nobel-Str. 10, 40789 Monheim (DE). (81) Bestimmungsstaaten (soweit nicht anders angegeben, fiir jede verfiigbare nationale Schutzrechtsart): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Bestimmungsstaaten (soweit nicht anders angegeben, fiir jede verfiigbare regionale Schutzrechtsart)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), eurasisches (AM, AZ, BY, KG, KZ, RU, TJ, TM), europaisches (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Erklarungen gemaB Regel 4.17 : hinsichtlich der Berechtigung des Anmelders, ein Patent zu beantragen und zu erhalten (Regel 4.17 Ziffer ii) Veroffentlicht: — mit internationalem Recherchenbericht (Artikel 21 Absatz V (54) Title: METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS (54) Bezeichnung : VERFAHREN ZUR HERSTELLUNG VON TRIAZOL-VERBINDUNGEN (') AA Keto-Form BB Enol-Form CJ i> i-H cn i-H o CJ o & AA Keto form BB Enol form (57) Abstract: The present invention relates to a method for the preparation of l-[ 6-(morpholino-4-yl)-pyrimidino-4-yl]-4-(lH- l,2,3-triazolo-l-yl)-lH-pyrazolo-5-ol (I - enol form) or 2-[6-(morpholino-4-yl)-pyrimidino-4-yl]-4-(lH-l,2,3-triazolo-l-yl)-l,2- dihydro-3H-pyrazolo-3-one (I - keto form) and sodium-l-[6-(morpholino-4-yl)-pyrimidino-4-yl]-4-(lH-l,2,3-triazolo-l-yl)-lH- pyrazolo-5-olate (II) starting from 1, 2,3-triazole (HI), methylbromoacetate (IV-Me-Br) or ethylbromoacetate (IV-Et-Br), 4,6- dichloropyrimidine (VIII), morpholine (IX) and hydrazine (XII). (57) Zusammenfassung: Die vorliegende Erfmdung betrifft ein Verfahren zur Herstellung von l-[6-(Morpholin-4-yl)pyrimidin-4- yl]-4-(lH-l,2,3-triazol-l-yl)-lH-pyrazol-5-ol (I - Enol-Form) bzw. 2-[6-(Morpholin-4-yl)pyrimidin-4-yl]-4-(lH-l,2,3-triazol-l-yl)- l,2-dihydro-3H-pyrazol-3-on (I - Keto-Form) und Natrium-l-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(lH-l,2,3-triazol-l-yl)-lH- pyrazol-5-olat (II) ausgehend vonl,2,3-Triazol (HI), Bromessigsauremethylester (IV-Me-Br) oder Bromessigsaureethylester (IV-Et- Br), 4,6-Dichlorpyrimidin (VIII), Morpholin (IX) und Hydrazin (XII).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167152 | 2012-05-08 | ||
| PCT/EP2013/059418 WO2013167552A1 (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407043PA true SG11201407043PA (en) | 2014-12-30 |
Family
ID=48325714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407043PA SG11201407043PA (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
| SG10201609319YA SG10201609319YA (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609319YA SG10201609319YA (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10301289B2 (en) |
| EP (1) | EP2847183B1 (en) |
| JP (1) | JP6149104B2 (en) |
| KR (1) | KR102086389B1 (en) |
| CN (1) | CN104411704B (en) |
| AP (1) | AP2014008089A0 (en) |
| AU (1) | AU2013258107B2 (en) |
| BR (1) | BR112014027564B1 (en) |
| CA (1) | CA2872726C (en) |
| CL (2) | CL2014003003A1 (en) |
| CO (1) | CO7121324A2 (en) |
| CR (1) | CR20140514A (en) |
| CU (1) | CU20140128A7 (en) |
| DK (1) | DK2847183T3 (en) |
| DO (1) | DOP2014000254A (en) |
| EA (1) | EA027804B1 (en) |
| ES (1) | ES2641205T3 (en) |
| HK (1) | HK1208027A1 (en) |
| HR (1) | HRP20171321T1 (en) |
| HU (1) | HUE034430T2 (en) |
| IL (1) | IL235441A (en) |
| LT (1) | LT2847183T (en) |
| MX (1) | MX350519B (en) |
| MY (1) | MY184577A (en) |
| NZ (1) | NZ701661A (en) |
| PE (1) | PE20142453A1 (en) |
| PH (1) | PH12014502482A1 (en) |
| PL (1) | PL2847183T3 (en) |
| PT (1) | PT2847183T (en) |
| RS (1) | RS56255B1 (en) |
| SG (2) | SG11201407043PA (en) |
| SI (1) | SI2847183T1 (en) |
| TN (1) | TN2014000469A1 (en) |
| UA (1) | UA116349C2 (en) |
| WO (1) | WO2013167552A1 (en) |
| ZA (1) | ZA201408571B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017259872B2 (en) * | 2016-05-03 | 2021-06-24 | Bayer Pharma Aktiengesellschaft | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives |
| CN108084099B (en) * | 2017-12-20 | 2019-01-29 | 天驰药业有限公司 | A kind of synthetic method of 1,2,3- 3-triazole compounds |
| US10702525B1 (en) | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
| EP3888684A1 (en) | 2020-03-31 | 2021-10-06 | Bayer Animal Health GmbH | Composition having improved voluntary acceptance |
| CN114264752B (en) * | 2021-12-29 | 2023-08-15 | 北京金城泰尔制药有限公司 | Detection method of methyl bromoacetate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK135184A (en) | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | TRIAZOL (4.3-C) - AND TRIAZOL (1.5-C) PYRIMIDINES |
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| US4752910A (en) | 1984-10-30 | 1988-06-21 | Prime Computer, Inc. | Method and apparatus for continuous after-imaging |
| UY27813A1 (en) * | 2002-05-31 | 2003-12-31 | Smithkline Beecham Corp | PEPTIDE-DISFORMILASE INHIBITORS |
| AR042052A1 (en) | 2002-11-15 | 2005-06-08 | Vertex Pharma | USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES |
| WO2005044785A1 (en) * | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| DE102008020113A1 (en) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituted dihydropyrazolones and their use |
| CA2605899C (en) | 2005-04-26 | 2011-02-08 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| EP1885713A1 (en) | 2005-05-18 | 2008-02-13 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| DE102006050516A1 (en) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure |
| DE102010041236A1 (en) * | 2010-09-23 | 2012-03-29 | Osram Ag | Optoelectronic semiconductor component |
| DE102010044131A1 (en) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituted sodium 1H-pyrazole-5-olate |
-
2013
- 2013-05-06 KR KR1020147033989A patent/KR102086389B1/en active IP Right Grant
- 2013-05-06 AP AP2014008089A patent/AP2014008089A0/en unknown
- 2013-05-06 NZ NZ701661A patent/NZ701661A/en unknown
- 2013-05-06 AU AU2013258107A patent/AU2013258107B2/en active Active
- 2013-05-06 EP EP13720943.3A patent/EP2847183B1/en active Active
- 2013-05-06 CN CN201380036548.5A patent/CN104411704B/en active Active
- 2013-05-06 ES ES13720943.3T patent/ES2641205T3/en active Active
- 2013-05-06 JP JP2015510775A patent/JP6149104B2/en active Active
- 2013-05-06 MX MX2014013448A patent/MX350519B/en active IP Right Grant
- 2013-05-06 SG SG11201407043PA patent/SG11201407043PA/en unknown
- 2013-05-06 LT LTEP13720943.3T patent/LT2847183T/en unknown
- 2013-05-06 PL PL13720943T patent/PL2847183T3/en unknown
- 2013-05-06 UA UAA201413001A patent/UA116349C2/en unknown
- 2013-05-06 MY MYPI2014703274A patent/MY184577A/en unknown
- 2013-05-06 SG SG10201609319YA patent/SG10201609319YA/en unknown
- 2013-05-06 RS RS20170869A patent/RS56255B1/en unknown
- 2013-05-06 PE PE2014001942A patent/PE20142453A1/en active IP Right Grant
- 2013-05-06 EA EA201492032A patent/EA027804B1/en not_active IP Right Cessation
- 2013-05-06 CA CA2872726A patent/CA2872726C/en active Active
- 2013-05-06 SI SI201330768T patent/SI2847183T1/en unknown
- 2013-05-06 PT PT137209433T patent/PT2847183T/en unknown
- 2013-05-06 HU HUE13720943A patent/HUE034430T2/en unknown
- 2013-05-06 WO PCT/EP2013/059418 patent/WO2013167552A1/en active Application Filing
- 2013-05-06 DK DK13720943.3T patent/DK2847183T3/en active
- 2013-05-06 BR BR112014027564-5A patent/BR112014027564B1/en active IP Right Grant
- 2013-05-06 US US14/399,929 patent/US10301289B2/en active Active
-
2014
- 2014-11-02 IL IL235441A patent/IL235441A/en active IP Right Grant
- 2014-11-04 CO CO14243310A patent/CO7121324A2/en unknown
- 2014-11-06 CU CU2014000128A patent/CU20140128A7/en unknown
- 2014-11-06 CL CL2014003003A patent/CL2014003003A1/en unknown
- 2014-11-06 PH PH12014502482A patent/PH12014502482A1/en unknown
- 2014-11-07 TN TN2014000469A patent/TN2014000469A1/en unknown
- 2014-11-07 DO DO2014000254A patent/DOP2014000254A/en unknown
- 2014-11-07 CR CR20140514A patent/CR20140514A/en unknown
- 2014-11-21 ZA ZA2014/08571A patent/ZA201408571B/en unknown
-
2015
- 2015-09-08 HK HK15108703.4A patent/HK1208027A1/en unknown
-
2016
- 2016-05-13 CL CL2016001165A patent/CL2016001165A1/en unknown
-
2017
- 2017-08-31 HR HRP20171321TT patent/HRP20171321T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201407043PA (en) | Method for the preparation of triazole compounds | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201808214TA (en) | Pyrazolopyrimidine derivatives | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201804672QA (en) | Systems and methods for production of low oxygen content silicon | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201806855WA (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy |